文献速递产科母胎医学

高危妊娠孕早期晚阶段母体心脏功能与形态学在随后发生胎儿生长受限和/或子痫前期中的表现

Early third-trimester maternal cardiac function and morphometry in high-risk pregnancies that subsequently developed fetal growth restriction and/or pre-eclampsia.
PubMed 文献 · Ultrasound Obstet Gynecol · 2026-11-08

这项前瞻性队列研究纳入948例高危单胎妊娠,于27+0至28+6周行母体超声心动图。随后发生胎儿生长受限和/或子痫前期者心输出量降低、全身血管阻力升高;胎儿生长受限表型表现为前负荷降低而无心动过速,孤立性子痫前期表型表现为高血压特征伴心率代偿性升高。

要点

  • 随后发生胎儿生长受限和/或子痫前期的孕妇在27+0至28+6周即已出现心输出量降低和全身血管阻力升高。
  • 胎儿生长受限表型以左室舒张末内径减小提示前负荷降低,且不伴心动过速。
  • 孤立性子痫前期表型以平均动脉压最高、心率升高及左室壁厚度增加为特征。

核心结论

  • 母体心血管改变可能先于胎儿生长受限和子痫前期的发生,且因表型而异。
  • 随后发生胎儿生长受限和/或子痫前期的妊娠表现为心输出量降低,但胎儿生长受限反映为前负荷降低而无心动过速,孤立性子痫前期则表现为高血压特征伴心率代偿性升高。
  • 作者认为母体超声心动图可能有助于早期风险分层并指导高危妊娠的个体化监测和治疗。

研究设计与样本

  • 前瞻性队列研究,纳入2022年8月至2024年8月在西班牙巴塞罗那医院诊所母胎医学部因常规中孕期胎儿畸形筛查转诊的高危单胎妊娠。
  • 于27+0至28+6周进行评估,仅纳入评估时未诊断胎儿生长受限或子痫前期者,随访中识别随后发生胎儿生长受限和/或子痫前期者。
  • 最终分析共948例,其中129例随后发生胎儿生长受限和/或子痫前期(包括59例发生胎儿生长受限(伴或不伴子痫前期)和70例发生孤立性子痫前期),819例为无并发症妊娠。
  • 行母体超声心动图评估心输出量、每搏量、全身血管阻力及结构参数(左室壁厚度和心腔容积)。
  • 采用中位数分位数回归对心输出量和全身血管阻力进行多变量分析,校正体重指数,胎儿生长受限和子痫前期分别独立评估。

主要发现

  • 胎儿生长受限(伴或不伴子痫前期)组中位平均动脉压82.0 mmHg vs 无并发症组79.7 mmHg(P=0.027);孤立性子痫前期组84.8 mmHg vs 无并发症组79.7 mmHg(P<0.001);孤立性子痫前期组平均动脉压最高(孤立性子痫前期 vs 胎儿生长受限(伴或不伴子痫前期),P=0.047)。
  • 孤立性子痫前期组中位心率82.5 bpm vs 胎儿生长受限(伴或不伴子痫前期)组77.0 bpm(P=0.03)。
  • 多变量分析显示胎儿生长受限和子痫前期在发生前均独立与较低心输出量和较高全身血管阻力相关。
  • 胎儿生长受限(伴或不伴子痫前期)组中位每搏量59.7 mL vs 无并发症组64.2 mL(P=0.030);孤立性子痫前期组61.1 mL vs 无并发症组64.2 mL(P=0.016)。
  • 胎儿生长受限(伴或不伴子痫前期)组中位体重指数校正心输出量0.18 (L/min)/(kg/m2) vs 无并发症组0.19 (L/min)/(kg/m2)(P=0.005);孤立性子痫前期组0.17 (L/min)/(kg/m2) vs 无并发症组0.19 (L/min)/(kg/m2)(P=0.001)。

临床怎么用

  • 作者认为母体超声心动图可能有助于早期风险分层,并指导高危妊娠的个体化监测和治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate maternal cardiovascular function and cardiac morphology in early third-trimester pregnancies at high risk for fetal growth restriction (FGR) and compare findings between pregnancies that subsequently developed FGR and/or pre-eclampsia (PE) and uncomplicated pregnancies. METHODS: This prospective cohort study included singleton pregnancies at high risk for FGR referred to the Maternal-Fetal Medicine Department at the Hospital Clinic of Barcelona, Barcelona, Spain, between August 2022 and August 2024, for a routine second-trimester fetal anomaly scan. The patients were assessed between 27 + 0 and 28 + 6 weeks' gestation and were only included in the analysis if they did not have a diagnosis of FGR or PE at the time of evaluation; those who subsequently developed FGR and/or PE were identified during follow-up. Maternal echocardiography was performed to assess cardiac output (CO), stroke volume (SV), systemic vascular resistance (SVR) and structural parameters including left ventricular (LV) wall thickness and chamber volumes. Results were compared between pregnancies that subsequently developed FGR (with or without PE), pregnancies that subsequently developed isolated PE and uncomplicated pregnancies. Multivariable analysis was performed using quantile regression of the medians for CO and SVR, adjusted for body mass index (BMI), with FGR and PE assessed independently. RESULTS: A total of 948 patients were included in the final analysis, of whom 129 developed FGR and/or PE (including 59 that developed FGR (with or without PE) and 70 that developed isolated PE) and 819 had uncomplicated pregnancies. Median mean arterial pressure (MAP) was higher in the FGR (with or without PE) group (82.0 mmHg) and the isolated-PE group (84.8 mmHg) than in the uncomplicated group (79.7 mmHg; P = 0.027 and P < 0.001, respectively), with the isolated-PE group showing the highest MAP values (isolated PE vs FGR (with or without PE), P = 0.047). Median heart rate was elevated in the isolated-PE group (82.5 bpm) compared with the FGR (with or without PE) group (77.0 bpm; P = 0.03). In the multivariable analysis, FGR and PE were associated independently with lower CO and higher SVR prior to their development. Median SV was reduced in the FGR (with or without PE) group (59.7 mL) and the isolated-PE group (61.1 mL) compared with the uncomplicated group (64.2 mL; P = 0.030 and P = 0.016, respectively). Median BMI-indexed CO was also lower in the FGR (with or without PE) group (0.18 (L/min)/(kg/m2)) and the isolated-PE group (0.17 (L/min)/(kg/m2)) compared with the uncomplicated group (0.19 (L/min)/(kg/m2); P = 0.005 and P = 0.001, respectively). Median SVR was elevated in the FGR (with or without PE) group (1393 dynes × s/cm5) and the isolated-PE group (1339 dynes × s/cm5) compared with the uncomplicated group (1252 dynes × s/cm5; P < 0.001 and P = 0.01, respectively). Compared with the uncomplicated group, the isolated-PE group showed greater median LV myocardial thickness at end diastole (0.50 vs 0.47 cm; P = 0.003), interventricular septal thickness at end diastole (0.92 vs 0.89 cm; P = 0.031), posterior wall thickness at end diastole (0.98 vs 0.94 cm; P = 0.013) and relative wall thickness (0.45 vs 0.42; P = 0.001). Moreover, the FGR (with or without PE) group had a smaller median LV end-diastolic diameter (4.27 cm) compared with the uncomplicated group (4.48 cm; P = 0.003), indicating that preload may be reduced in patients who developed FGR (with or without PE). LV mass indexed for BMI was similar across groups. CONCLUSIONS: Maternal cardiovascular alterations may precede the development of FGR and PE and differ by phenotype. Pregnancies that subsequently developed FGR and/or PE showed reduced CO, but those that developed FGR reflected lower preload without tachycardia, while those that developed isolated PE showed hypertensive features with a compensatory rise in heart rate. Maternal echocardiography may aid early risk stratification and guide tailored surveillance and therapy in pregnancies at high risk for FGR. © 2026 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Martinez-Egea J, Daza M, Pumarola C, et al. Early third-trimester maternal cardiac function and morphometry in high-risk pregnancies that subsequently developed fetal growth restriction and/or pre-eclampsia. Ultrasound Obstet Gynecol. 2026. PMID: 42999945. doi:10.1002/uog.70367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。